| Literature DB >> 29135361 |
Jae-Ik Han1, Haerin Rhim1, Cheol-Ho Yang2, Hee-Myung Park2.
Abstract
BACKGROUND: High prevalence of methicillin resistance among clinical isolates of Staphylococcus pseudintermedius obtained from dogs was reported in Seoul metropolitan area, South Korea. However, no information on genetic lineage and clonal spread is currently available.Entities:
Keywords: Dog; Staphylococcus pseudintermedius; antibiogram; canine; genetic lineage
Mesh:
Substances:
Year: 2018 PMID: 29135361 PMCID: PMC6830971 DOI: 10.1080/01652176.2017.1400710
Source DB: PubMed Journal: Vet Q ISSN: 0165-2176 Impact factor: 3.320
Molecular characteristics of the 29 Staphylococcus pseudintermedius strains isolated from healthy dogs.
| Antimicrobial resistance profile | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MR | Strain | MLST | SCC | CLI | TE | P | CHL | KAN | SYN | VAN | GEN | TMP | E | CIP | SMX | AUG | SXT | POD | OXA | TIM | DOX | FAZ | |
| MR | 7 | 361 | N | V | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | ||||
| 26 | 363 | N | V | R | R | R | R | R | |||||||||||||||
| 31 | 363 | N | V | R | R | R | R | R | R | ||||||||||||||
| 29 | 364 | N | N | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | |||||
| 34 | 365 | t02 | V | R | R | R | R | R | R | R | R | R | R | R | R | ||||||||
| 70 | 365 | t02 | V | R | R | R | R | R | R | R | R | R | R | R | R | ||||||||
| 78 | 365 | t02 | V | R | R | R | R | R | R | R | R | R | R | R | |||||||||
| 157 | 365 | t02 | V | R | R | R | R | R | R | R | R | R | R | R | R | R | R | ||||||
| 175 | 365 | t02 | V | R | R | R | R | R | R | R | R | R | R | R | |||||||||
| 46 | 366 | N | V | R | R | R | R | R | R | R | R | R | |||||||||||
| 48 | 367 | t06 | V | R | R | R | R | R | R | R | |||||||||||||
| 50 | 368 | N | V | R | R | ||||||||||||||||||
| 76 | 370 | N | V | R | R | R | R | R | R | R | R | R | R | R | R | ||||||||
| 133 | 371 | t06 | V | R | R | R | R | R | R | R | R | R | R | ||||||||||
| 101 | 372 | t06 | V | R | R | R | R | R | R | R | R | R | R | ||||||||||
| 152 | 373 | N | V | R | R | R | R | R | R | R | R | R | R | R | |||||||||
| 86 | 54 | N | V | R | R | R | R | R | R | R | R | ||||||||||||
| 66 | 112 | t06 | N | R | R | R | R | R | R | R | R | R | R | R | R | R | R | R | |||||
| 103 | 121 | t06 | V | R | R | R | R | R | R | R | R | R | R | R | |||||||||
| 149 | 309 | N | V | R | R | R | R | R | R | R | R | R | R | R | |||||||||
| MS | 15 | 373 | N | NT | R | ||||||||||||||||||
| 38 | 374 | N | NT | R | |||||||||||||||||||
| 40 | 375 | N | NT | ||||||||||||||||||||
| 44 | 376 | N | NT | R | R | R | R | R | R | R | R | R | R | ||||||||||
| 60 | 377 | t73 | NT | R | R | R | R | R | R | R | R | R | R | ||||||||||
| 62 | 378 | t06 | NT | R | R | R | R | R | R | R | R | R | R | ||||||||||
| 63 | 379 | t73 | NT | R | R | R | R | R | R | R | R | R | R | ||||||||||
| 84 | 380 | N | NT | R | R | R | R | R | R | R | |||||||||||||
| 104 | 381 | N | NT | R | |||||||||||||||||||
| Resistance breakpoint for antimicrobials | ≥4 | ≥16 | ≥0.25 | ≥32 | ≥64 | ≥4 | ≥16 | ≥16 | ≥16 | ≥8 | ≥4 | ≥512 | >8/4 | ≥4/76 | ≥8 | ≥4 | ≥16/2 | ≥16 | ≥32 | ||||
aMR, methicillin-resistance; MS, methicillin-susceptible.
bMLST, multilocus sequence type.
cN, no amplification in PCR.
dNT, not tested.
eCLI, clindamycin; TE, tetracycline; P, penicillin; CHL, chloramphenicol; KAN, kanamycin; SYN, Quinupristin/dalfopristin; VAN, vancomycin; GEN, gentamicin; TMP, trimethoprim; E, erythromycin; CIP, ciprofloxacin; SMX, sulfamethoxazole; AUG, amoxicillin/clavulanate; SXT, trimethoprim/sulfamethoxazole; POD, cefpodoxime; OXA, oxacillin; TIM, ticarcillin/clavulanate; DOX, doxycycline; FAZ, cefazoline.
fR, resistant.
gReferences, CLSI M100-S17 (for AUG, POD, TIM and FAZ) and M100-S24 (for all the other antimicrobial agents).
Concurrent detection of antibiotic resistance in S. pseudintermedius isolates and the strength of the association.
| Reference antibiotics | Associated antibiotics | Odds ratio | 95% CI | |
|---|---|---|---|---|
| Oxacillin | Tetracycline | 0.033 | 7.1 | 1.2–42.8 |
| Trimethoprim | 0.033 | 7.1 | 1.2–42.8 | |
| Tetracycline | Oxacillin | 0.033 | 7.1 | 1.2–42.8 |
| Kanamycin | 0.008 | 15.8 | 2.1–122.1 | |
| Gentamicin | 0.019 | 9.6 | 1.5–63.5 | |
| Trimethoprim | 0.001 | 140.0 | 7.7–2550.4 | |
| Erythromycin | 0.036 | 11.4 | 1.2–110.4 | |
| Sulfamethoxazole | 0.048 | 12.0 | 1.0–141.3 | |
| Trimethoprim/Sulfamethoxazole | 0.036 | 11.4 | 1.2–110.4 | |
| Kanamycin | Tetracycline | 0.008 | 15.8 | 2.1–122.1 |
| Gentamicin | 0.012 | 20.4 | 2.0–211.8 | |
| Trimethoprim | 0.008 | 15.8 | 2.1–122.1 | |
| Sulfamethoxazole | 0.031 | 15.8 | 1.3–192.5 | |
| Doxycycline | 0.044 | 10.5 | 1.1–103.5 | |
| Gentamicin | Tetracycline | 0.019 | 9.6 | 1.5–63.5 |
| Kanamycin | 0.012 | 20.4 | 2.0–211.8 | |
| Trimethoprim | 0.019 | 9.6 | 1.5–63.5 | |
| Doxycycline | 0.009 | 11.7 | 1.8–74.2 | |
| Trimethoprim | Oxacillin | 0.033 | 7.1 | 1.2–42.8 |
| Tetracycline | 0.001 | 140.0 | 7.7–2550.4 | |
| Kanamycin | 0.008 | 15.8 | 2.1–122.1 | |
| Gentamicin | 0.019 | 9.6 | 1.5–63.5 | |
| Erythromycin | 0.036 | 11.4 | 1.2–110.4 | |
| Sulfamethoxazole | 0.048 | 12.0 | 1.0–141.3 | |
| Trimethoprim/sulfamethoxazole | 0.036 | 11.4 | 1.2–110.4 | |
| Doxycycline | 0.023 | 14.0 | 1.4–137.3 | |
| Erythromycin | Tetracycline | 0.036 | 11.4 | 1.2–110.4 |
| Trimethoprim | 0.036 | 11.4 | 1.2–110.4 | |
| Sulfamethoxazole | Tetracycline | 0.048 | 12.0 | 1.0–141.3 |
| Penicillin | 0.049 | 11.5 | 1.0–131.3 | |
| Kanamycin | 0.031 | 15.8 | 1.3–192.5 | |
| Trimethoprim | 0.048 | 12.0 | 1.0–141.3 | |
| Penicillin | Sulfamethoxazole | 0.049 | 11.5 | 1.0–131.3 |
| Amoxicillin/clavulanate | Cefazoline | 0.003 | 92.0 | 4.7–1790.1 |
| Trimethoprim/sulfamethoxazole | Tetracycline | 0.036 | 11.4 | 1.2–110.4 |
| Trimethoprim | 0.036 | 11.4 | 1.2–110.4 | |
| Cefpodoxime | 0.047 | 5.3 | 1.0–27.8 | |
| Doxycycline | 0.008 | 10.1 | 1.8–56.0 | |
| Cefpodoxime | Doxycycline | 0.018 | 9.0 | 1.5–55.5 |
| Trimethoprime/sulfamethoxazole | 0.047 | 5.3 | 1.0–27.8 | |
| Doxycycline | Kanamycin | 0.044 | 10.5 | 1.1–103.5 |
| Gentamicin | 0.009 | 11.7 | 1.8–74.2 | |
| Trimethoprim | 0.023 | 14.0 | 1.4–137.3 | |
| Trimethoprim/sulfamethoxazole | 0.008 | 10.1 | 1.8–56.0 | |
| Cefpodoxime | 0.018 | 9.0 | 1.5–55.5 | |
| Cefazoline | Amoxicillin/clavulanate | 0.003 | 92.0 | 4.7–1790.1 |
Figure 1.Population snapshot of Staphylococcus pseudintermedius. Clusters of related sequence types (STs) from the S. pseudintermedius database are displayed as a single eBURST diagram, by setting the group definition to zero of seven shared alleles. Clusters of linked isolates correspond to clonal complexes. The STs identified in the present study are marked in blue (new STs) or purple (previously identified STs) numbers, and previously identified STs are shown with symbols: open blue circle = exclusive to Europe; open red squares = exclusive to North America; open triangles = found in Europe and North America; open blue circles with dotted lines = found in both Europe and Asia; open diamonds = Asia.